Bristol-Myers, Ono Pharmaceutical sales and marketing update

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that Opdivo nivolumab from Bristol-Myers Squibb has added overall survival benefit in treatment-naive patients with BRAF V600 mutation-negative melanoma. The human IgG4 mAb against PD-1 has “considerable” added benefit in men, and “minor” added benefit in women. IQWiG said Opdivo had “no hint of added benefit” in other patient groups due to non-evaluable data provided from BMS. ...